The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells

Journal of Neuroimmunology

Volumn 149, Issue 1-2, 2004, Pages 167-181

  Hayez, Nathalie ^a   Harfi, Issam ^a   Lema Kisoka, Roger ^a   Svoboda, Michal ^b   Corazza, Francis ^c   Sariban, Eric ^a,d  

^a HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^d Hôpital des Enfants   (Belgium)

Author keywords

Calcium; cAMP; Myeloid leukemia; Neuropeptides; PACAP; VIP

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; CYCLIC AMP; GLYCOPHORIN A; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROPEPTIDE; PERTUSSIS TOXIN; PHOSPHOLIPASE C; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BLAST CELL; BONE MARROW CELL; CALCIUM CELL LEVEL; CANCER CELL CULTURE; CANCER PATIENT; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG EFFECT; EXPOSURE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATE; BROMODEOXYURIDINE; CALCIUM; CELL LINE, TUMOR; CYCLIC AMP; CYTARABINE; CYTOSOL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRENES; FLOW CYTOMETRY; GLYCOPHORIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INOSITOL PHOSPHATES; INTERCELLULAR ADHESION MOLECULE-1; LEUKEMIA; MYELOID CELLS; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PYRROLIDINONES; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; THROMBIN; TIME FACTORS; TRANSCRIPTION FACTOR AP-1; VASOACTIVE INTESTINAL PEPTIDE;

EID: 1542500762     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2003.12.008     Document Type: Article

References (65)

1. Brass L.F., Manning D.R., Williams A.G., Woolkalis M.J., Poncz M. Receptor and G protein-mediated responses to thrombin in HEL cells. J. Biol. Chem. 26:1991;958-965.
2. Chedeville A., Mirossay L., Chastre E., Hurbain-Kosmath I., Lopez M., Gespach C. Interaction of VIP, PACAP and related peptides on human leukemic human monocytes and macrophages. FEBS Lett. 319:1993;171-176.
3. Chevalier S., Praloran V., Smith C., MacGrogan D., Ip N.Y., Yancopoulos G.D., Brachet P., Pouplard A., Gascan H. Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells. Blood. 83:1994;1479-1485.
4. 2+ channel currents in vascular smooth muscle cells: involvement of PKC and PKA. FASEB J. 10:1996;1310-1317.
5. Choi S.-Y., Chae H.-D., Park T.-J., Ha H., Kim K.-T. Characterization of high affinity neurotensin receptor NTR1 in HL-60 cells and its down regulation during granulocytic differentiation. Br. J. Pharmacol. 126:1999;1050-1056.
6. Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK sigma pathway in endotoxin-activated microglia. Biochem. Biophys. Res. Commun. 293:2002;771-776.
7. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypetide inhibit interleukin-12 transcription by regulating nuclear fact kappaB and Ets activation. J. Biol. Chem. 274:1999;31930-31940.
8. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK sigma pathway in LPS-stimulated macrophages. J. Neuroimmunol. 110:2000;97-105.
9. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-κB- dependent gene activation at multiple levels in the human monocytic cell line THP-1. J. Biol. Chem. 276:2001;369-380.
10. Delgado M., Munoz-Elias E.J., Kan Y., Gozes I., Fridkin M., Brenneman D.E., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alfa transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J. Biol. Chem. 273:1998;31427-31436.
11. Delgado M., Martinez C., Pozo D., Calvo J.R., Leceta J., Ganea D., Gomariz R.P. Vasoactive intestinal peptide(VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J. Immunol. 162:1999;1200-1205.
12. Delgado M., Sun W., Leceta J., Ganea D. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. J. Immunol. 163:1999;4213-4223.
13. Delgado M., Abad C., Martinez C., Juarranz M.G., Arranz A., Gomariz R.P., Leceta J. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 80:2002;16-24.
14. Dorn G.W. II, Oswald K.J., McCluskey S., Kuhel D.G., Liggett S.B. α2-Adrenergic receptor stimulated Calcium release is transduced by Gi-associated G(βγ)-mediated activation of phospholipase C. Biochemistry. 36:1997;6415-6423.
15. Draoui M., Hida T., Jakowlew S., Birrer M., Zia F., Moody T.-W. PACAP stimulates c-fos mRNAs in small cell lung cancer cells. Life Sci. 59:1996;307-313.
16. Dunzendorfer S., Schratzberg P., Reinisch N., Kähler C.M., Wiedermann C.J. Secretoneurin, a novel neuropeptide, is a potent chemoattractant for human eosinophils. Blood. 91:1998;1527-1532.
17. El Zein N.et al. The neuropeptide PACAP is a physiological activator of human moncytes functions. Eur. J. Biochem. 270(Suppl. 1):2003;37-38. (PS01-0027).
18. Frühwald M.C., O'Dorisio M.S., Fleitz J., Pietsch T., Reubi J.C. Vasoactive intestinal peptide (VIP) and VIP receptors: gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood. Int. J. Cancer. 81:1999;165-173.
19. Gibellini D., Re M.C., Bassini A., Guidotti L., Catani L., La Placa M., Zauli G. HIV-1 gp120 induces the activation of both c-fos and c-jun immediate-early genes in HEL megakaryocytic cells. Br. J. Haematol. 104:1999;81-86.
20. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
21. Harfi I. The neuropeptide PACAP27 activates multiple biochemical pathways in human blood polymorphonuclear neutrophils (PMN). Eur. J. Biochem. 270(Suppl. 1):2003;183. (PS01-0754).
22. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol. Ther. 99:2003;25-44.
23. Holmgren S., Jensen J. Evolution of vertebrate neuropeptides. Brain Res. Bull. 55:2001;723-735.
24. Jiang S., Kopras E., McMichael M., Bell R.H. Jr., Ulrich C.D. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res. 57:1997;1475-1480.
25. Koski G.K., Schwartz G.N., Weng D.E., Gress R.E., Engels F.H., Tsokos M., Czerniecki B.J., Cohen P.A. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation stade, transformation status, or sensitivity to biologic agents. Blood. 9:1999;1359-1371.
26. Langer I., Perret J., Vertongen P., Waelbroeck M., Robberecht P. Vasoactive intestinal peptide (VIP) stimulates [Ca(2+)](i) and cyclic AMP in CHO cells expressing Gα16. Cell Calcium. 30:2001;229-234.
27. Langer I., Vertongen P., Perret J., Waelbroeck M., Robberecht P. A small sequence in the third intracellular loop of the VPAC1 receptor is responsible for its efficient coupling to the calcium effector. Mol. Endocrinol. 16:2002;1089-1096.
28. Leech C.A., Holz G.G., Habener J.F. Pituitary adenylate cyclase-activating polypeptide induces the voltage-independent activation of inward membrane currents and elevation of intracellular calcium in HIT-T15 insulinoma cells. Endocrinology. 136:1995;1530-1536.
29. Lelièvre V., Meunier A.C., Caigneaux E., Falcon J., Muller J.M. Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines. Cell. Signal. 10:1998;13-26.
30. Lelièvre V., Pineau N., Du J., Wen C.H., Nguyen T., Janet T., Muller J.M., Waschek J.A. Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. A novel VIP-independent action of PHI via MAP kinase. J. Biol. Chem. 273:1998;19685-19690.
31. Lema-Kisoka R., Hayez N., Langer I., Robberecht P., Sariban E., Delporte C. Characterization of functional VIP/PACAP receptors in human erythroleukemic HEL cell line. Peptides. 22:2001;2155-2162.
32. Leyton J., Coelho T., Coy D.-H., Jakowlew S., Birrer M.-J., Moody T.-W. PACAP(6-38) inhibits the growth of prostate cancer cells. Cancer Lett. 125:1998;131-139.
33. Lu N., DiCicco-Bloom E. Pituitary adenylate cyclase-activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3357-3362.
34. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leukoc. Biol. 63:1998;591-601.
35. Martinez C., Abad C., Delgado M., Arranz A., Juarranz M.G., Rodriguez-Henche N., Brabet P., Leceta J., Gomariz R.P. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1053-1058.
36. 3H]thymidine incorporation assay. Clin. Diagn. Lab. Immunol. 7:2000;687-692.
37. 2+ in human erythroleukemia cells. J. Biol. Chem. 264:1989;4986-4991.
38. Moody T.W., Zia F., Draoui M., Brenneman D.E., Fridkin M., Davidson A., Gozes I. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. U. S. A. 90:1993;4345-4349.
39. 2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am. J. Physiol. 255:1988;E880-E885.
40. Nagashima A.C., Giacomini D., Castro C.P., Pereda M.P., Renner U., Stal G.K., Arst E. Transcriptional regulation of interleukin-6 in pituitary folliculo stellate TtT/GF cells. Mol. Cell. Endocrinol. 201(1-2):2003;47-56. (Mar. 28).
41. O'Dorisio M.S., Shannon B.T., Fleshman D.J., Campolito L.B. Identification of high affinity receptors for vasoactive intestinal peptide on human lymphocytes of B cell lineage. J. Immunol. 142:1989;3533-3536.
42. Papayannopoulou T., Nakamoto B., Kurachi S., Nelson R. Analysis of the erythroid phenotype of HEL cells: clonal variation and the effect of inducers. Blood. 70:1987;1764-1772.
43. Park S.K., Olson T.A., Ercal N., Summers M., O'Dorisio M.S. Characterization of vasoactive intestinal peptide receptors on human megakaryocytes and platelets. Blood. 87:1996;4629-4635.
44. Rameshwar P., Gascon P. Induction of negative hematopoitic regulators by neurokinin-A in bone marrow stroma. Blood. 88:1996;98-106.
45. Rameshwar P., Ganea D., Gascon P. In vitro stimulatory effect of substance P on hematopoiesis. Blood. 81:1993;391-398.
46. Rameshwar P., Gascon P., Oh H.S., Denny T., Zhu G., Ganea D. Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. Exp. Hematol. 30:2002;1001-1009.
47. Rawlings S.R., Canny B.J., Leong D.A. Pituitary adenylate cyclase-activating polypeptide regulates cytosolic CA2+ in rat gonadotropes and somatotropes through different intracellular mechanisms. Endocrinology. 132:1993;1447-1452.
48. Robberecht P., De Neef P., Waelbroeck M., Tastenoy M., Christophe J. VIP and related peptides induce rapid homologous desensitization in the human lymphoma SUP T1 cell line. Peptides. 10:1989;441-446.
49. Ruchaud S., Lanotte M. cAMP and "death signals" in a myeloid leukemia cell: from membrane receptors to nuclear responses: a review. Biochem. Soc. Trans. 25:1997;410-415.
50. Schäfer H., Zheng J., Gundlach F., Günther R., Schmidt W.-E. PACAP stimulates transcription of c-fos and c-jun and activates the AP-1 transcription factor in rat pancreatic carcinoma cells. Biochem. Biophys. Res. Commun. 221:1996;111-116.
51. Schreiber E., Matthias P., Müller M.M., Scaffner W. Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. Nucleic Acids Res. 17:1989;6419.
52. Sherman M.L., Shafman T.D., Kufe D.W. Modulation of cyclic AMP levels and differentiation by adenosine analogs in mouse erythroleukemia cells. J. Cell. Physiol. 134:1988;429-436.
53. Susaki Y., Shimizu S., Katakura K., Watanabe N., Kawamoto K., Matsumoto M., Tsudzuki M., Furusaka T., Kitamura Y., Matsuda H. Functional properties of murine macrophages promoted by nerve growth factor. Blood. 88:1996;4630-4637.
54. 2+ release from ryanodine/caffeine stores through a novel pathway independent of both inositol trisphosphates and cyclic AMP in bovine adrenal medullary cells. J. Neurochem. 70:1998;1652-1661.
55. Tani T., Ylänne J., Virtanen I. Expression of megakaryocytic and erythroid properties in human leukemic cells. Exp. Hematol. 24:1996;158-168.
56. Tissot M., Mathieu J., Mirossay L., Thuret A., Giroud J.P. Polyphosphoinositide metabolism in polymorphonuclear cells from healthy and thermally injured rats:effect of the immunomodutator RU41740. J. Leukoc. Biol. 50:1991;607-614.
57. Vandenberghe P.A., Ceuppens J.L. Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with Fluo-3, a new fluorescent calcium indicator. J. Immunol. Methods. 127:1990;197-205.
58. Van Rampelbergh J., Poloczek P., Francoys I., Delporte C., Winand J., Robberecht P., Waelbroeck M. The pituitary adenylate cyclase- activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim. Biophys. Acta. 1357:1997;249-255.
59. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52:2000;269-324.
60. Vaudry D., Stork P.J., Lazarovici P., Eiden L.E. Signaling pathways for PC12 cell differentiation: making the right connections. Sciences. 296:2002;1648-1649.
61. Vertongen P., Camby I., Darro F., Kiss R., Robberecht P. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Neuropeptides. 30:1996;491-496.
62. Vertongen P., De Clerck P., Fournet J.C., Martelli H., Helardot P., Devalck C., Peeters T., Sariban E., Robberecht P. Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues. Neuropeptides. 31:1997;409-413.
63. Villalba M., Bockaert J., Journot L. Pituitary adenylate cyclase-activating polypeptide. (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J. Neurosci. 17:1997;83-90.
64. Wang H.Y., Jiang X.M., Ganea D. The neuropeptides VIP and PACAP inhibit IL-2 transcriptional decreasing c-Jun and increasing JunB expression in T cells. J. Neuroimmunol. 104:2000;68-78.
65. Zia H., Hida T., Jakowlew S., Birrer M., Gozes Y., Reubi J.C., Fridkin M., Gozes I., Moody T.W. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56:1996;3486-3489.